Anticipated Release Date: TBD Chemical indicators; Low-cost, easy to use, ultra-low SWaP modular open system based chemical detector that is widely distributed to the General Forces as an integrated kit for indication of chemical hazards; Read More
Anticipated Release Date: Q42027 Host response based test to predict illness severity. Responding to this opportunity requires membership in the Medical CBRN Defense Consortium (MCDC). This Consortium releases numerous solicitations throughout the year, so even if Read More
Anticipated Release Date: TBD FFBS Increment 2 will focus on automating the sample preparation process and meeting any key performance parameter thresholds that were not met during the development of FFBS Increment 1. This is Read More
Anticipated Release Date: Q4 2027 This opportunity requires membership in the Medical CBRN Defense Consortium (MCDC). This Consortium releases numerous opportunities throughout the year, so even if this one may not be right for you, we Read More
Anticipated Release Date: Q3FY26 FDA approval of a multi-drug autoinjector to reduce logistical burden on the warfighter and increase survivability. Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous Read More
Anticipated Release: TBD Chemical indicators; Low-cost, easy to use, ultra-low SWaP modular open system based chemical detector that is widely distributed to the General Forces as an integrated kit for indication of chemical hazards; Provide Read More
Anticipated Release: Q4FY27 Host response based test to predict illness severity. Responding to this opportunity requires membership in the Countering Weapons of Mass Destruction (CWMD) Consortium. This Consortium releases numerous solicitations throughout the year, so even Read More
Anticipated Release Date: TBD This topic aims to provide novel, low-burden masks for the general purpose warfighter utilizing innovative materials and custom manufacturing processes. These materials and processes will make these masks bespoke to users’ Read More
Anticipated Release Date: Q2 FY27: Modification of existing Accelerated Antibodies agreement for additional monoclonal antibody prototype. Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so Read More
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2024 - All rights reserved.